-$0.66 EPS Expected for Nevro Corp (NVRO) This Quarter

Wall Street brokerages predict that Nevro Corp (NYSE:NVRO) will post ($0.66) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Nevro’s earnings. The highest EPS estimate is ($0.59) and the lowest is ($0.80). Nevro posted earnings of ($0.59) per share in the same quarter last year, which would suggest a negative year over year growth rate of 11.9%. The firm is expected to issue its next earnings results on Monday, May 6th.

On average, analysts expect that Nevro will report full-year earnings of ($2.31) per share for the current year, with EPS estimates ranging from ($2.48) to ($1.91). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.67) per share, with EPS estimates ranging from ($2.28) to ($1.06). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that follow Nevro.

Nevro (NYSE:NVRO) last issued its quarterly earnings results on Thursday, February 21st. The medical equipment provider reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.15). The company had revenue of $107.90 million during the quarter, compared to the consensus estimate of $107.39 million. Nevro had a negative return on equity of 20.13% and a negative net margin of 12.70%. The firm’s quarterly revenue was up 10.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.15) earnings per share.



A number of analysts recently issued reports on the company. ValuEngine upgraded Nevro from a “sell” rating to a “hold” rating in a research report on Wednesday, March 20th. Morgan Stanley upgraded Nevro from an “underweight” rating to an “overweight” rating and lifted their target price for the stock from $41.00 to $70.00 in a research report on Wednesday, March 20th. Wells Fargo & Co upgraded Nevro from a “market perform” rating to an “outperform” rating and set a $75.00 target price for the company in a research report on Wednesday, March 20th. Canaccord Genuity lifted their target price on Nevro from $46.00 to $62.00 and gave the stock a “buy” rating in a research report on Wednesday, March 20th. Finally, Bank of America upgraded Nevro from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $50.00 to $70.00 in a research report on Wednesday, March 20th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $62.67.

NVRO traded down $0.35 during trading on Tuesday, reaching $64.11. The company had a trading volume of 496,982 shares, compared to its average volume of 709,573. The company has a market cap of $2.00 billion, a PE ratio of -39.09 and a beta of 0.21. Nevro has a 52 week low of $34.75 and a 52 week high of $94.34. The company has a quick ratio of 5.64, a current ratio of 7.11 and a debt-to-equity ratio of 0.62.

Several large investors have recently added to or reduced their stakes in the company. Deutsche Bank AG increased its position in shares of Nevro by 24.1% in the fourth quarter. Deutsche Bank AG now owns 307,606 shares of the medical equipment provider’s stock valued at $11,961,000 after buying an additional 59,763 shares in the last quarter. MUFG Securities EMEA plc purchased a new stake in shares of Nevro in the fourth quarter valued at approximately $4,721,000. Geode Capital Management LLC increased its position in shares of Nevro by 9.3% in the fourth quarter. Geode Capital Management LLC now owns 308,995 shares of the medical equipment provider’s stock valued at $12,016,000 after buying an additional 26,356 shares in the last quarter. Norges Bank purchased a new stake in shares of Nevro in the fourth quarter valued at approximately $36,675,000. Finally, HRT Financial LLC increased its position in shares of Nevro by 103.0% in the fourth quarter. HRT Financial LLC now owns 7,416 shares of the medical equipment provider’s stock valued at $288,000 after buying an additional 3,762 shares in the last quarter.

Nevro Company Profile

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Featured Article: Cost of Goods Sold (COGS)

Get a free copy of the Zacks research report on Nevro (NVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.